Self-Reported Medication Adherence Measured with Morisky Scales in Rare Disease Patients: A Systematic Review and Meta-Analysis
-
Published:2023-05-31
Issue:11
Volume:11
Page:1609
-
ISSN:2227-9032
-
Container-title:Healthcare
-
language:en
-
Short-container-title:Healthcare
Author:
García-Muñoz Ana María1ORCID, Victoria-Montesinos Desirée1ORCID, Cerdá Begoña1ORCID, Ballester Pura1ORCID, de Velasco Eloisa María1, Zafrilla Pilar1ORCID
Affiliation:
1. Faculty of Pharmacy and Nutrition, Universidad Católica San Antonio de Murcia (UCAM), Campus de los Jerónimos, 30107 Murcia, Spain
Abstract
Background: The visibility of Rare Diseases is a new challenge for society. These diseases are numerous, heterogeneous in nature and distribution, characterized by a high mortality rate but low prevalence, and usually presenting a severe evolution. Adherence to medication studies in rare diseases are uncommon, due to treatment scarcity. Objectives: The main purpose of this study is to do a meta-analysis, evaluating the level of adherence to medication in the most prevalent rare diseases. Methods: This work is a systematic review, and meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (Registration number: CRD42022372843) and conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Adherence to treatment in this systematic review and meta-analysis was collected from all studies included, based on the crude numerators and denominators reported, using either the Morisky Medication Adherence Scale 4 or -8. Results: A total of 54 records were identified through database searches, or after screening relevant manuscripts’ references. Finally, 18 studies were included in this systematic review and meta-analysis. A total of 1559 participants (54.18% women) aged less than 84 years old were included. Twelve studies used the MMAS-8. In 8 of them, they established the level of adherence to treatment in three categories (low, medium, and high), with the mean prevalence in each of them being 41.4%, 30.4%, and 28.2%, respectively. Conclusions: The results observed in adherence to treatment in patients with rare diseases show great variability, due to the different aspects involved in the greater or lesser applicability of the medication.
Subject
Health Information Management,Health Informatics,Health Policy,Leadership and Management
Reference66 articles.
1. Belzer, L.T., Wright, S.M., Goodwin, E.J., Singh, M.N., and Carter, B.S. (2022). Psychosocial Considerations for the Child with Rare Disease: A Review with Recommendations and Calls to Action. Children, 9. 2. Collin-Histed, T., Gershkowitz, J., Stevens, B., and Timmins, G. (2022). Lysosomal Storage Disorders, John Wiley & Sons, Ltd. 3. Estimating Cumulative Point Prevalence of Rare Diseases: Analysis of the Orphanet Database;Lambert;Eur. J. Hum. Genet.,2020 4. EURODIS (2022, December 19). What Is a Rare Disease?. Available online: https://www.eurordis.org/information-support/what-is-a-rare-disease/. 5. Hedley, V., Hannah, M., Charlotte, R., and Ségolène, A. (2018). Report on the State of the Art of Rare Disease Activities in Europe, European Commission.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|